[go: up one dir, main page]

UA92504C2 - Anti-myostatin monoclonal antibody - Google Patents

Anti-myostatin monoclonal antibody

Info

Publication number
UA92504C2
UA92504C2 UAA200803004A UAA200803004A UA92504C2 UA 92504 C2 UA92504 C2 UA 92504C2 UA A200803004 A UAA200803004 A UA A200803004A UA A200803004 A UAA200803004 A UA A200803004A UA 92504 C2 UA92504 C2 UA 92504C2
Authority
UA
Ukraine
Prior art keywords
antibodies
monoclonal antibody
myostatin monoclonal
myostatin
increasing
Prior art date
Application number
UAA200803004A
Other languages
English (en)
Ukrainian (uk)
Inventor
Джулиан Дейвис
Брайан Эдвард Джоунз
Эндрю Игор Коритко
Памела Джин Митчелл
Розамунд Керол Смит
О'Брайан, (Ни Тобайас) Линда О.
Жун Ван
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of UA92504C2 publication Critical patent/UA92504C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)

Abstract

Изобретение относится к антителу, которое специфически связывается с миостатином (GDF-8). Изобретение также относится к фармацевтической композиции, которая его содержит, а также к применению данного антитела при изготовлении лекарственного средства для повышения мышечной массы, слабости, кахексии, истощения мышц и т.п.
UAA200803004A 2005-10-12 2006-05-10 Anti-myostatin monoclonal antibody UA92504C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72573805P 2005-10-12 2005-10-12

Publications (1)

Publication Number Publication Date
UA92504C2 true UA92504C2 (en) 2010-11-10

Family

ID=37681692

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200803004A UA92504C2 (en) 2005-10-12 2006-05-10 Anti-myostatin monoclonal antibody

Country Status (22)

Country Link
US (2) US7632499B2 (ru)
EP (2) EP1951755B1 (ru)
JP (1) JP5031756B2 (ru)
KR (1) KR101128548B1 (ru)
CN (1) CN101282992B (ru)
AU (1) AU2006303921B2 (ru)
BR (1) BRPI0617345A2 (ru)
CA (1) CA2624935C (ru)
DK (2) DK1951755T3 (ru)
EA (1) EA015903B1 (ru)
ES (2) ES2533462T3 (ru)
HR (1) HRP20150176T1 (ru)
HU (1) HUE036566T2 (ru)
IL (1) IL189580A (ru)
LT (1) LT2816058T (ru)
NO (1) NO20082167L (ru)
PL (2) PL1951755T3 (ru)
PT (2) PT2816058T (ru)
RS (2) RS54046B1 (ru)
SI (2) SI2816058T1 (ru)
UA (1) UA92504C2 (ru)
WO (1) WO2007047112A2 (ru)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058988A2 (en) 2002-12-20 2004-07-15 Amgen, Inc. Binding agents which inhibit myostatin
CN101277976B (zh) 2005-10-06 2012-04-11 伊莱利利公司 抗肌抑制素抗体
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
IN2014DN10515A (ru) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
HRP20130320T1 (en) * 2006-09-05 2013-05-31 Eli Lilly And Company Anti-myostatin antibodies
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
WO2009125825A1 (ja) 2008-04-11 2009-10-15 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
ES2861592T3 (es) 2008-06-25 2021-10-06 Novartis Ag Anticuerpos estables y solubles que inhiben el TNF
DK2307458T3 (en) 2008-06-25 2018-07-16 Esbatech Alcon Biomed Res Unit Humanization of rabbit antibodies using a universal antibody framework
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
TW201210612A (en) 2010-06-03 2012-03-16 Glaxo Group Ltd Humanised antigen binding proteins
JP2013537425A (ja) 2010-08-16 2013-10-03 アムジエン・インコーポレーテツド ミオスタチンに結合するポリペプチド、組成物および方法
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
EP4231014A3 (en) 2010-11-30 2024-08-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
EP2554353B1 (de) 2011-08-05 2017-06-07 Trisa Holding AG Verfahren zur Herstellung einer Zahnbürste und Zahnbürste
SMT201800092T1 (it) * 2011-11-14 2018-03-08 Regeneron Pharma Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a
DK2889377T3 (da) 2012-08-24 2020-03-30 Chugai Pharmaceutical Co Ltd Fc?RIIb-Specifik Fc-regionsvariant
EP2889376A4 (en) 2012-08-24 2016-11-02 Chugai Pharmaceutical Co Ltd MOUSE FC RII SPECIFIC FC ANTIBODY
AU2013315482B2 (en) 2012-09-13 2018-03-15 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
HK1214504A1 (zh) 2012-10-24 2016-07-29 细胞基因公司 用於治療貧血的方法
WO2014119634A1 (ja) * 2013-01-30 2014-08-07 独立行政法人国立精神・神経医療研究センター 筋増加剤及びそれを含む医薬組成物
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
EP3816625B1 (en) 2013-05-06 2025-09-17 Scholar Rock, Inc. Compositions and methods for growth factor modulation
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
CN105992951A (zh) 2014-01-27 2016-10-05 诺华股份有限公司 预测肌萎缩的生物标志物、方法和用途
WO2016073906A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
JP6706617B2 (ja) 2014-11-06 2020-06-10 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型−ミオスタチン抗体およびその使用
TWI808330B (zh) 2014-12-19 2023-07-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
US20180031579A1 (en) 2015-02-12 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
JP6877357B2 (ja) * 2015-04-15 2021-05-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法
JP7107836B2 (ja) * 2015-09-15 2022-07-27 スカラー ロック インコーポレイテッド 抗プロ／潜在型ミオスタチン抗体およびその使用
KR20230027321A (ko) 2015-12-18 2023-02-27 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
JP7141336B2 (ja) * 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
CN109071645A (zh) 2016-01-08 2018-12-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
US10946036B2 (en) 2016-06-13 2021-03-16 Scholar Rock, Inc. Use of myostatin inhibitors and combination therapies
KR102680483B1 (ko) 2016-06-17 2024-07-01 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체 및 사용 방법
RU2766112C2 (ru) 2016-08-05 2022-02-08 Чугаи Сейяку Кабусики Кайся Композиция для профилактики или лечения связанных с il-8 заболеваний
US11155611B2 (en) 2017-01-06 2021-10-26 Scholar Rock, Inc. Compositions and methods for making and using anti-myostatin antibodies
CA3092334A1 (en) 2018-03-01 2019-09-06 Regeneron Pharmaceuticals, Inc. Methods for altering body composition
US11608381B2 (en) 2018-04-06 2023-03-21 Regeneron Pharmaceuticals, Inc. Methods of treatment using a leptin receptor agonist antibody
CN119896730A (zh) 2018-12-17 2025-04-29 雷维托普有限公司 双免疫细胞衔接物
WO2020131910A1 (en) 2018-12-18 2020-06-25 Regeneron Pharmaceuticals, Inc. Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a
EP4590698A1 (en) 2022-09-21 2025-07-30 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction
EP4638496A1 (en) 2022-12-22 2025-10-29 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
DE69333082T2 (de) 1992-02-11 2004-05-06 Cell Genesys, Inc., Foster City Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
JPH09507829A (ja) 1993-03-19 1997-08-12 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子−８
PT1378572E (pt) 1993-05-12 2007-01-31 Genetics Inst Composições de bmp-11
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US6008434A (en) * 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
CA2194660C (en) * 1994-07-08 2009-09-29 Se-Jin Lee Growth differentiation factor-11
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
ATE352613T1 (de) 1995-08-29 2007-02-15 Kirin Brewery Chimäres tier und methode zu dessen herstellung
US20020165350A1 (en) 1996-11-13 2002-11-07 Tasuku Honjo Novel polypeptide, a method of producing it, and utility of the polypeptide
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
WO1999024057A2 (en) 1997-11-07 1999-05-20 Genetics Inst Neuronal uses of bmp-11
GB2333706A (en) 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
AU2586199A (en) 1998-02-05 1999-08-23 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
DE69941116D1 (de) * 1998-05-06 2009-08-27 Metamorphix Inc G von gdf-8
MXPA01007366A (es) * 1999-01-21 2002-06-04 Metamorphix Inc Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos.
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
MXPA05002648A (es) * 2002-09-16 2005-08-19 Wyeth Corp Activacion de miostatina por metaloproteasa, y metodos para modular la actividad de miostatina.
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
WO2004058988A2 (en) * 2002-12-20 2004-07-15 Amgen, Inc. Binding agents which inhibit myostatin
KR20060026860A (ko) 2003-06-02 2006-03-24 와이어쓰 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도
WO2005005604A2 (en) 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
NZ529860A (en) 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
BRPI0418317A (pt) 2003-12-31 2007-05-02 Schering Plough Ltd vacina de aumento de crescimento à base de epitopo de neutralização
ES2384176T3 (es) 2004-03-23 2012-07-02 Eli Lilly & Company Anticuerpos anti-miostatina
CA2575563A1 (en) 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
AU2006226878A1 (en) 2005-03-23 2006-09-28 Wyeth Detection of GDF-8 modulating agents
EA015534B1 (ru) 2005-04-25 2011-08-30 Пфайзер Инк. Антитела к миостатину и способы их применения
WO2006128190A2 (en) 2005-05-27 2006-11-30 The Regents Of The University Of California Compositions and methods for treatment of neural disorders using transforming growth factor-beta superfamily proteins and their antagonists
ES2534760T3 (es) 2005-08-19 2015-04-28 Wyeth Llc Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8
CN101277976B (zh) 2005-10-06 2012-04-11 伊莱利利公司 抗肌抑制素抗体
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
JP2009518422A (ja) 2005-12-06 2009-05-07 アムジェン インコーポレイテッド ミオスタチン・アンタゴニストの使用
US20070190056A1 (en) 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
HRP20130320T1 (en) 2006-09-05 2013-05-31 Eli Lilly And Company Anti-myostatin antibodies
TWI454479B (zh) 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途

Also Published As

Publication number Publication date
US20090131638A1 (en) 2009-05-21
SI2816058T1 (en) 2018-02-28
PL2816058T3 (pl) 2018-05-30
JP5031756B2 (ja) 2012-09-26
WO2007047112A3 (en) 2007-08-16
HK1118564A1 (en) 2009-02-13
ES2533462T3 (es) 2015-04-10
JP2009511579A (ja) 2009-03-19
ES2657292T3 (es) 2018-03-02
EP2816058A1 (en) 2014-12-24
KR20080049104A (ko) 2008-06-03
EP1951755A2 (en) 2008-08-06
AU2006303921A1 (en) 2007-04-26
PT2816058T (pt) 2018-02-27
CA2624935C (en) 2011-11-29
AU2006303921B2 (en) 2011-05-12
EA015903B1 (ru) 2011-12-30
WO2007047112A2 (en) 2007-04-26
IL189580A (en) 2012-07-31
US20100080811A1 (en) 2010-04-01
HUE036566T2 (hu) 2018-07-30
EP1951755B1 (en) 2015-01-07
CA2624935A1 (en) 2007-04-26
HRP20150176T1 (xx) 2015-03-27
EA200801065A1 (ru) 2008-08-29
PT1951755E (pt) 2015-03-16
SI1951755T1 (sl) 2015-02-27
RS56755B1 (sr) 2018-04-30
DK2816058T3 (en) 2018-01-22
DK1951755T3 (en) 2015-01-19
RS54046B1 (sr) 2015-10-30
US8066995B2 (en) 2011-11-29
US7632499B2 (en) 2009-12-15
CN101282992A (zh) 2008-10-08
KR101128548B1 (ko) 2012-03-23
EP2816058B1 (en) 2017-12-13
PL1951755T3 (pl) 2015-05-29
LT2816058T (lt) 2018-03-12
CN101282992B (zh) 2013-02-13
NO20082167L (no) 2008-07-10
BRPI0617345A2 (pt) 2011-07-26
IL189580A0 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
UA92504C2 (en) Anti-myostatin monoclonal antibody
NO20064788L (no) Anti-myostatin-anistoffer
MX2024004322A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
IL185754A0 (en) Novel anti-plgf antibody
WO2007044411A3 (en) Anti-myostatin antibodies
TN2009000383A1 (en) Anti - sclerostin antibodies
EP4248996A3 (en) Anti-trem2 antibodies and methods of use thereof
EA200870050A1 (ru) Анти-il-17-антитела
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
DE602006013029D1 (de) Anti-egfr-antikörper
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
WO2017152102A3 (en) Anti-trem1 antibodies and methods of use thereof
WO2016081746A3 (en) Antibodies comprising modified heavy constant regions
WO2003034903A3 (en) Psma antibodies and protein multimers
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
WO2007101021A3 (en) Humanized anti-ghrelin antibodies
CY1115979T1 (el) Αντισωματα κατα της μυοστατινης
EA201992324A1 (ru) Анти-trem2 антитела и способы их применения
EA201992797A1 (ru) Антитела, содержащие модифицированные константные области тяжелой цепи
EA201992319A1 (ru) Анти-cd33 антитела и способы их применения
UA94245C2 (en) Anti-il-17 antibodies
HK1154251A1 (zh) 抗人类α-干扰素的人类化抗体